MA55205A - Formulations injectables prêtes à l'emploi - Google Patents

Formulations injectables prêtes à l'emploi

Info

Publication number
MA55205A
MA55205A MA055205A MA55205A MA55205A MA 55205 A MA55205 A MA 55205A MA 055205 A MA055205 A MA 055205A MA 55205 A MA55205 A MA 55205A MA 55205 A MA55205 A MA 55205A
Authority
MA
Morocco
Prior art keywords
ready
injectable formulations
use injectable
formulations
injectable
Prior art date
Application number
MA055205A
Other languages
English (en)
Inventor
Todd P Foster
Vijaya Bharti Joshi
Laibin Luo
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MA55205A publication Critical patent/MA55205A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA055205A 2019-03-06 2020-03-05 Formulations injectables prêtes à l'emploi MA55205A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962814440P 2019-03-06 2019-03-06

Publications (1)

Publication Number Publication Date
MA55205A true MA55205A (fr) 2022-01-12

Family

ID=70009447

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055205A MA55205A (fr) 2019-03-06 2020-03-05 Formulations injectables prêtes à l'emploi

Country Status (13)

Country Link
US (1) US12295958B2 (fr)
EP (1) EP3934618A1 (fr)
JP (1) JP7323630B2 (fr)
KR (1) KR102671650B1 (fr)
AU (1) AU2020232306B2 (fr)
BR (1) BR112021017536A2 (fr)
CA (1) CA3132159C (fr)
IL (1) IL285520B2 (fr)
MA (1) MA55205A (fr)
MX (1) MX2021010689A (fr)
PH (1) PH12021551973A1 (fr)
WO (1) WO2020181024A1 (fr)
ZA (1) ZA202105883B (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557615C2 (de) 1975-12-20 1985-08-14 Bayer Ag, 5090 Leverkusen Neue Niclosamid-Suspensionsformulierungen
US5318781A (en) 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
AU8832301A (en) 2000-09-12 2002-03-26 Upjohn Co Pharmaceutical composition having modified carrier
US6911441B2 (en) 2002-12-16 2005-06-28 Akzo Nobel N.V. Prolonged release pharmaceutical composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
CN1517090A (zh) * 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
US20040214753A1 (en) 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
CN1569000A (zh) 2003-07-16 2005-01-26 王玉万 含头孢菌素的速效并长效注射剂
JP5685193B2 (ja) * 2008-11-19 2015-03-18 メリアル リミテッド セフチオフルおよびケトプロフェンとまたはセフチオフルとベンジルアルコールとを含む製剤
WO2012095438A1 (fr) 2011-01-12 2012-07-19 Intervet International B.V. Particules et suspensions d'antibiotiques céphalosporine
MY167596A (en) 2011-12-23 2018-09-20 Bayer New Zealand Ltd Antibiotic formulations
WO2013129944A1 (fr) * 2012-02-27 2013-09-06 Bayer New Zealand Limited Compositions à libération contrôlée et leurs procédés d'utilisation
AU2013262611B2 (en) * 2012-05-18 2018-03-01 Genentech, Inc. High-concentration monoclonal antibody formulations
KR102677903B1 (ko) * 2017-11-07 2024-06-21 인터벳 인터내셔널 비.브이. 주사가능한 이속사졸린 제약 조성물 및 그의 기생충 침입에 대한 용도
CN108578362A (zh) 2018-05-30 2018-09-28 河北维尔利动物药业集团有限公司 一种头孢维星混悬注射液及其制备方法

Also Published As

Publication number Publication date
US20220125798A1 (en) 2022-04-28
IL285520B1 (en) 2024-09-01
NZ779449A (en) 2023-11-24
PH12021551973A1 (en) 2022-05-23
KR20210120084A (ko) 2021-10-06
US12295958B2 (en) 2025-05-13
WO2020181024A1 (fr) 2020-09-10
JP2022523573A (ja) 2022-04-25
CA3132159C (fr) 2023-11-21
KR102671650B1 (ko) 2024-06-04
IL285520A (en) 2021-09-30
MX2021010689A (es) 2021-10-01
AU2020232306B2 (en) 2023-11-16
IL285520B2 (en) 2025-01-01
AU2020232306A1 (en) 2021-09-02
JP7323630B2 (ja) 2023-08-08
ZA202105883B (en) 2023-03-29
BR112021017536A2 (pt) 2021-11-09
CA3132159A1 (fr) 2020-09-10
EP3934618A1 (fr) 2022-01-12

Similar Documents

Publication Publication Date Title
MA46696A (fr) Formulations injectables à dose unique prêtes à l'emploi
EP3850794A4 (fr) Configuration prête à l'emploi de fronthaul destinée à un c-ran
EP3400016A4 (fr) Formulations injectables à longue durée d'action
EP3989959A4 (fr) Formulations transdermiques
EP4043002A4 (fr) Composition dentaire
EP3820490A4 (fr) Compositions d'aav
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
EP3860585A4 (fr) Compositions thérapeutiques
DK3725355T3 (da) Indpakket præcisionssmurt intermitterende urinkateter klar til brug
EP3820980A4 (fr) Compositions d'esterquats
EP3917910A4 (fr) Composés et compositions thérapeutiques
EP3868371A4 (fr) Nouvelle composition pharmaceutique
EP3864058A4 (fr) Composition photodurcissable
EP3313380A4 (fr) Composition pour l'administration d'agents actifs à un animal
EP4044995C0 (fr) Compositions d'hygiène buccale
EP4044996C0 (fr) Composition d'hygiène buccale
EP4029491A4 (fr) Composition dentaire polymérisable
EP3977855A4 (fr) Composition microbicide stable
EP3974026A4 (fr) Composition destinée à améliorer la fonction hépatique
EP3793561A4 (fr) Composés médicamenteux antiviraux et composition associée
MA55205A (fr) Formulations injectables prêtes à l'emploi
EP3949952A4 (fr) Composition médicinale
EP4009939A4 (fr) Composition de soins personnels
EP3892256A4 (fr) Composition cosmétique
EP3749662A4 (fr) Composés et compositions thérapeutiques